M. A. Nauck
Liraglutide and cardiovascular outcomes in type 2 diabetes
New England Journal of Medicine.
LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations
Diabetes, Obesity & Metabolism.
LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial
American Heart Journal.
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Lancet (London, England).
Map of science